Skip to main content
Public beta This website is in public beta – please give your feedback.

Example clinical scenario

A neonate is born with erythroderma. In addition, the skin is peeling and there are blisters and erosions in areas. The team looking after the patient is concerned about a potential infection, as well as epidermolysis bullosa or ichthyosis.

When to consider genomic testing

  • Many causes of epidermal differentiation disorders (EDDs) are covered in R165 Ichthyosis and erythokeratoderma. To be eligible for this test, the patient must have at least two features from this list:
    • born with collodion membrane;
    • erythroderma;
    • dark plate-like scales or fine white scaling;
    • ectropium/eclabium; and/or
    • hyperkeratosis.
  • There are cases in which other clinical indications should be considered, including a number of rarer causes of ‘collodion baby’:
    • infantile Gaucher disease (R272);
    • ectodermal dysplasias (R163);
    • neutral lipid storage disease with ichthyosis (R166); and
    • Conradi-Hünermann-Happle syndrome (R166).

What do you need to do?

  • Consult the National Genomic Test Directory. From here you can access the rare and inherited disease eligibility criteria, which provides information about individual tests and their associated eligibility criteria. You can also access a spreadsheet containing details of all available tests.
  • To find out which genes are included on different gene panels, see the NHS Genomic Medicine Service (GMS) Signed Off Panels Resource.
  • Decide which of the tests best suits the needs of your patient and/or family.
    • If the presentation best fits a palmoplantar EDD, please consider R166 Palmoplantar keratodermas. This clinical indication includes WES or gene panel sequencing and MLPA.
    • If skin fragility is a prominent feature, consider R164 Epidermolysis bullosa and congenital skin fragility. This clinical indication includes WES or gene panel sequencing and MLPA.
    • Rarer causes of ‘collodion baby’ that are not included in R165 require other clinical indications, as outlined above.
  • For tests that do not include whole genome sequencing, including R165, R166, R272 and R163:
    • parental samples may be needed for interpretation of the child’s result; these can be taken alongside that of the child, and their DNA stored, or can be requested at a later date if needed.
  • The majority of tests are DNA-based, and an EDTA sample (typically a purple-topped tube) is required. Exceptions include karyotype testing and DNA repair defect testing (for chromosome breakage), which require lithium heparin (typically a green-topped tube).
  • Information about patient eligibility and test indications was correct at the time of writing. When requesting a test, please refer to the National Genomic Test Directory to confirm the right test for your patient.

Resources

For clinicians

References:

For patients

↑ Back to top
  • Last reviewed: 05/09/2025
  • Next review due: 05/09/2026
  • Authors: Dr Mark Eisner
  • Reviewers: Dr Adam Jackson, Professor Neil Rajan